AbbVie balance sheet
At the end of fiscal 2025, AbbVie had total assets of $133.96bn and shareholders' equity of −$3.27bn. It held $5.23bn in cash against $67.50bn of debt: net debt of $62.27bn.
Balance sheet
| Fiscal year | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.0 | 5.9 | 9.6 | 8.3 | 8.4 | 5.1 | 9.3 | 7.3 | 39.9 | 8.4 | 9.7 | 9.2 | 12.8 | 5.5 | 5.2 | 10.8 |
| Receivables | — | 4.3 | 3.9 | 3.7 | 4.7 | 4.8 | 5.1 | 5.4 | 5.4 | 8.8 | 10.0 | 11.3 | 11.2 | 10.9 | 12.6 | 13.5 |
| Inventory | — | 1.1 | 1.2 | 1.1 | 1.7 | 1.4 | 1.6 | 1.6 | 1.8 | 3.3 | 3.1 | 3.6 | 4.1 | 4.2 | 5.0 | 5.3 |
| Total current assets | — | 15.4 | 17.8 | 16.1 | 16.3 | 16.2 | 21.2 | 16.9 | 49.5 | 24.2 | 27.9 | 28.5 | 33.0 | 25.6 | 29.1 | 37.5 |
| Goodwill | 6.1 | 6.1 | 6.3 | 5.9 | 13.2 | 15.4 | 15.8 | 15.7 | 15.6 | 33.1 | 32.4 | 32.2 | 32.3 | 35.0 | 35.6 | 37.8 |
| Total assets | — | 27.0 | 29.2 | 27.5 | 53.1 | 66.1 | 70.8 | 59.4 | 89.1 | 150.6 | 146.5 | 138.8 | 134.7 | 135.2 | 134.0 | 147.7 |
| Accounts payable | — | 0.6 | 0.9 | 1.4 | 1.6 | 1.4 | 1.5 | 1.5 | 1.5 | 2.3 | 2.9 | 2.9 | 3.7 | 2.9 | 3.6 | — |
| Total current liabilities | — | 6.8 | 6.9 | 11.4 | 10.9 | 9.8 | 16.6 | 17.2 | 15.6 | 28.7 | 35.2 | 29.5 | 37.8 | 38.7 | 43.3 | 43.1 |
| Short-term debt | — | 1.0 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.5 | 0.0 |
| Long-term debt | — | 14.6 | 14.3 | 10.5 | 29.2 | 36.4 | 31.0 | 35.0 | 67.2 | 84.9 | 76.0 | 63.1 | 59.2 | 66.8 | 64.5 | 72.2 |
| Total debt | 0.0 | 15.7 | 14.7 | 15.0 | 31.7 | 36.8 | 37.4 | 40.3 | 67.2 | 86.1 | 76.7 | 63.3 | 59.4 | 67.1 | 67.5 | 80.9 |
| Shareholders' equity | — | −0.4 | 4.5 | 1.7 | 3.9 | 4.6 | 5.1 | −8.4 | −8.2 | 13.1 | 15.4 | 17.3 | 10.4 | 3.3 | −3.3 | −4.6 |
| Net debt (negative = net cash) | −0.0 | 9.8 | 5.1 | 6.6 | 23.3 | 31.7 | 28.1 | 33.0 | 27.3 | 77.6 | 66.9 | 54.1 | 46.6 | 61.6 | 62.3 | 70.1 |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Receivables | 10.9 | 12.5 | 12.6 | 12.8 | 12.6 | 12.5 | 13.8 | 13.5 |
| Inventory | 4.2 | 4.5 | 5.0 | 4.9 | 5.0 | 5.0 | 5.1 | 5.3 |
| Total current assets | 25.6 | 27.7 | 29.3 | 28.5 | 29.1 | 33.5 | 33.7 | 37.5 |
| Goodwill | 35.0 | 35.3 | 35.6 | 35.6 | 35.6 | 35.6 | 35.5 | 37.8 |
| Total assets | 135.2 | 136.2 | 137.2 | 133.9 | 134.0 | 136.5 | 135.1 | 147.7 |
| Accounts payable | 2.9 | — | — | — | 3.6 | — | — | — |
| Total current liabilities | 38.7 | 36.4 | 39.8 | 39.4 | 43.3 | 42.1 | 41.6 | 43.1 |
| Short-term debt | 0.0 | 1.6 | 5.6 | 3.8 | 2.5 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 66.8 | 64.5 | 63.0 | 63.0 | 64.5 | 64.5 | 62.5 | 72.2 |
| Total debt | 66.8 | 66.1 | 68.5 | 66.8 | 67.0 | 64.5 | 62.5 | 72.2 |
| Shareholders' equity | 3.3 | 1.4 | −0.2 | −2.6 | −3.3 | −6.7 | −5.9 | −4.6 |
Compare with peers
- Amgen balance sheet
- Gilead Sciences balance sheet
- Regeneron Pharmaceuticals balance sheet
- Vertex Pharmaceuticals balance sheet
- Biogen balance sheet
Head to head: ABBV vs AMGNABBV vs GILDABBV vs REGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies